Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_8259



Chemical Information
Antiviral agent IDDrugRepV_8259
Antiviral agent nameLinifanib
IUPAC Name1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea PubChem
SMILES (canonical)CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N PubChem
Molecular FormulaC21H18FN5O PubChem
Molecular Weight (g/mol)375.407 PubChem
InChlInChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28) PubChem
Structural Information
  
Clinical Information
Biological Information
Secondary Indication Vaccinia virus (VACV) NA NAWorld Health OrganisationCDC
Secondary Indication (Approaches)Experimental
Secondary Indication (Methods)In-vitro
Secondary Indication (Model system) [cell lines/ animal models]HeLa cells
Secondary Indication (Viral titer)0.01 MOI
Secondary Indication (Mode of drug delivery) Culture
Secondary Indication (Duration of drug delivery)24 hours
Secondary Indication (Drug concentration)10 μM
Secondary Indication (Change)Decrease
Secondary Indication (Type of Inhibition) Percent inhibition [ 60.5 % ]
ReferencePeng C, Zhou Y, Cao S, Pant A, Campos Guerrero ML, McDonald P, Roy A, Yang Z..Identification of Vaccinia Virus Inhibitors and Cellular Functions Necessary for Efficient Viral Replication by Screening Bioactives and FDA-Approved Drugs..Vaccines (Basel). 2020 Jul 21;8(3):E401. doi: 10.3390/vaccines8030401. PMID:32708182 PubMed
CommentA customized compound library was screened that contained over 3200 bioactives and FDA (Food and Drug Administration)-approved chemicals, most having known cellular targets, for their inhibitory effects on VACV replication. We identified over 140 compounds that suppressed VACV replication. Many of these hits target cellular pathways previously reported to be required for efficient VACV replication, validating the effectiveness of our screening.